Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

• Main Authors: Katya Corado (Author), Kara Chew (Author), Mark Giganti (Author), Ying Mu (Author), Courtney Fletcher (Author), Judith Currier (Author), Eric Daar (Author), David Wohl (Author), Jonathan Li (Author), Carlee Moser (Author), Justin Ritz (Author), Arzhang Javan (Author), Gene Neytman (Author), Marina Caskey (Author), Michael Hughes (Author), Davey Smith (Author), Joseph Eron (Author), ACTIV-2/A5401 Study Team (Author)
• Format: Book
• Published: Case Western Reserve University, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Outpatient COVID-19 monoclonal antibody (mAb) treatment via subcutaneous delivery, if effective, overcomes the logistical burdens of intravenous administration. Methods: ACTIV-2/A5401 was a randomized, masked placebo-controlled platform trial where participants with COVID-19 at low risk...